Drug Type Oncolytic virus |
Synonyms Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus, recombinant human IL12/15-PDL1B HSV-1 oncolytic virus Injection, 重组人IL12/15-PDL1B单纯疱疹I型溶瘤病毒 + [3] |
Target |
Mechanism IL-12R stimulants(Interleukin-12 receptor stimulants), IL-15Rα stimulants(Interleukin-15 receptor subunit alpha stimulants), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Virogin Biotech Ltd.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteosarcoma | Phase 2 | CN | 27 Jul 2023 | |
Metastatic gastric adenocarcinoma | Phase 2 | CN | 06 Mar 2023 | |
Metastatic gastroesophageal adenocarcinoma | Phase 2 | CN | 06 Mar 2023 | |
Cholangiocarcinoma | Phase 2 | CA | Virogin Biotech Ltd.Startup | 27 Jul 2022 |
Intrahepatic Cholangiocarcinoma | Phase 2 | CN | 14 May 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | CN | 08 Mar 2022 | |
Hepatocellular Carcinoma | Phase 2 | - | Virogin Biotech Ltd.Startup | 04 Feb 2022 |
Primary Malignant Liver Neoplasm | Phase 2 | CN | 16 Mar 2021 | |
Solid tumor | Discovery | AU | Virogin Biotech Ltd.Startup | 28 Feb 2021 |